# A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

> **NCT02306876** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-06412562 3mg BID
- **DRUG:** PF-06412562 15mg BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02306876
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-19
- **Primary completion:** 2016-06-14
- **Final completion:** 2016-06-14
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study was not terminated for reasons of safety.
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02306876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02306876, "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02306876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*